A Strong Leadership Team
FUJIFILM Diosynth Biotechnologies is led by a seasoned team of executives.Their cumulative knowledge and combined professional backgrounds add up to unparalleled leadership that keeps our organization a step ahead of the industry and in sync with our customers’ needs. Their collective vision is to be the global biologics and vaccine CDMO partner of choice through continuous technology innovation, superior service, and commitment to quality. It is the strength and spirit of our leadership team that guides us in our daily mission to make a positive contribution to society by supporting the development of novel lifesaving treatments.
Chief Executive Officer
Martin Meeson is a seasoned executive who brings extensive global experience to the Biotech and Pharmaceutical markets.
Martin was named Chief Executive Officer on April 1st, 2020 after serving as Chief Operating Officer and President at of our US FDB operations (North Carolina and Texas). Previously Martin served as Chief Financial Officer for the US. Prior to this, Martin worked for the Fujifilm Diosynth organization for over 6 years, holding leadership positions at the United Kingdom site, including Head of Finance and IT. Before joining Fujifilm Diosynth he was Finance Director at Oxford Chemicals where he was responsible for all aspects of Finance, IT, and Purchasing. He has also held leadership positions at Hibernia Foods, ICI/Dupont and KPMG.
Chief Operating Officer, Billingham, UK site
Paul is responsible for all delivery operations at the Billingham site. He is a chartered chemical engineer and a lean six sigma Black Belt with over 15 years’ experience in chemical, pharmaceutical and biologics manufacturing.
Since joining Avecia Biologics in 2003 as senior process engineer, he has held various positions in engineering, business planning and project management until taking on his current role. Prior to joining the company he held various engineering positions with Monsanto Chemicals and GlaxoSmithKline.
Chief Operating Officer, Hillerød, DK site
Lars has 25+ years of experience in Life Science working in Site Management, Operations, Manufacturing and Engineering with the companies Biogen, Genentech, Novo Nordisk, Novozymes and NNE. He has worked and executed projects in Europe, China and the US. Focus has been on Leadership and development, Project Management, Strategic Projects, Organizational Design, Automation and Conceptual Design.
He has made significant contributions to Modular and Fast Track Concepts resulting in unparallelled project schedule. Through 2017-2019 he was the Site Head of Large Scale Biologics and Finished goods of the Biogen (Denmark) Manufacturing site in Hillerod and responsible for 800 employees with excellent result in Safety, Quality and reliability. The site has three doubled in output over this period.
Lars holds a Master’s degree from the Technical University of Denmark.
Chief Operating Officer, RTP, North Carolina Site
Christine Vannais is a seasoned professional with over twenty years of experience working in a variety of industries including contract biopharmaceutical development and manufacturing, USDA biological vaccine manufacturing and research, FDA and EU small molecule manufacturing, primary and secondary packaging operations, API potent compound manufacturing, Department of Defense sites, among others.
Christine was announced as Chief Operating Officer of FDB’s North Carolina site on April 1, 2020. Christine joined FDB in 2012 and led the North Carolina Manufacturing Operations team starting in 2014 as part of the Site Leadership Team. In this role she was responsible for the site’s 24/7 manufacturing operations, which include cGMP production in both microbial and mammalian systems. Prior to joining FDB Christine help positions at MERCK Animal Health and Schering Plough Corporation. Christine was a Certified Safety Professional and is a graduate from Colorado State University.
Chief Operating Officer, College Station, Texas site
Gerry is responsible for the operation of the College Station, TX site. He has over 20 years’ experience in contract manufacturing and has been a part of the Diosynth team for the past 14 years holding roles in project management, development and manufacturing.
Most recently was the head of Process and Analytical Development and Process Sciences groups at the RTP site. Gerry has broad experience in the tech transfer, development, and manufacturing of customer programs from clinical supply through process validation up to and including commercial manufacturing.
Chief Scientific Officer
Chief Information Officer
As the Chief Information Officer, Ravi is responsible for the technology vision, roadmap and operations across all sites globally. Ravi has over 20 years of experience with a track record of building effective global teams, leading technology transformation, digital business, insights and business integration for Fortune 500 corporations across multiple compliance heavy industries – Biotechnology, Pharmaceuticals and Financial Services.
Prior to joining FUJIFILM Dioysnth Biotechnologies, he was CIO at Bioverativ and held divisional CIO roles at Pfizer. In addition, he delivered global strategic platforms in ERP, Digital, Infrastructure,Security to financial services companies as a principal at PriceWaterhouseCoopers and Deloitte Consulting. He has a BS in accounting, Masters degrees in Finance, Operations Management & Information Science and an MBA in Marketing.
Senior Vice President, Quality Operations
David is responsible for directing the development, implementation and maintenance of quality control, quality assurance and regulatory systems and activities across the FDB sites. He has 40+ years of experience in the pharmaceutical and medical device business, operating in the United States and Europe for various companies.
During his tenure at these positions he has been responsible for the compliance and regulatory approval of several facility expansions and successful Preapproval and routine inspections by the US FDA, Canadian, European, Japanese and several South American regulatory agencies. Dave is an ASQ certified Quality Engineer and Quality Auditor.
Chief Financial Officer
Michael Lyons was named Chief Financial Officer at FDB on April 1, 2020. Mike joined FDB in 2008 in the role of Financial Controller at our Billingham, U.K. site. During his tenure with the organization he served as Head of Finance at FDBK and CFO for FDB Europe. He is an accredited Lean Six Sigma Green Belt. Previous to joining our organization Mike held positions at Armstrong World Industries, Inc. and Caterpillar UK Ltd. Mike graduated with a BA (Hons) Business Studies and Finance from the University of Teesside and is currently a Fellow Chartered Management Accountant.
Chief Business Officer
Andy is responsible for all of the commercial, planning and program mangement functions at FUJIFILM Diosynth Biotechnologies. Andy has over 15 years experience in Biotechnology, having held roles in Manufacturing, Technology Transfer, Planning, Program Management and more recently as interim Head of Marketing and Sales. Andy has fulfilled these roles in both the UK and US sites.
Chief Transformation Officer
As Chief Transformation Officer, Christie Williams is responsible for the identification and delivery of a portfolio of strategic initiatives spanning process, organizational, and cultural excellence objectives aimed at improvements in quality, efficiency, and value. Christie has direct line management responsibility for the global ePMO and the Operational and Business Excellence functions and, in collaboration with the rest of the Global Leadership Team, ensures that global process excellence goals are aligned with business strategy and the One FDB operating principal.
Most recently, Christie Williams served as Compliance Officer for FDB locations in North Carolina and Texas, USA. She joined the company in 1998 as a downstream process development scientist at the North Carolina, U.S. site. In 2010, Christie led the deployment of Lean Six Sigma at the North Carolina site, achieved black belt certification, established the tier process, and led the delivery of a portfolio of improvement projects. During her tenure at the North Carolina site, she led the manufacturing sciences, program design, operational excellence, supply chain, program management, and cell culture manufacturing teams. In 2014, Christie joined the Texas site as part of the due diligence team and later the post-merger integration team.
Senior Director, Corporate Office
Keita Hirabayashi is responsible for FUJIFILM Corporation’s 80% interest in FUJIFILM Diosynth Biotechnologies and supporting the executive management team. He joined FDB in 2011 at RTP, North Carolina. Following this appointment, he moved to the company’s College Station, Texas site in 2014. In September 2019 Keita transferred to the company’s Hillerød, Denmark site.
Prior to moving from Tokyo to RTP in September 2011, he was responsible for the procurement, cost accounting, strategical planning and business development at FUJIFILM Corporation for more than 15 years.
Executive Vice President, Corporate Office – Business Strategy
Kenji is responsible for Mitsubishi Corporation’s 20% interest in FUJIFILM Diosynth Biotechnologies and supporting the Commercial Team. He moved from Billingham to RTP in December 2013.
Prior to moving from Tokyo to Billingham in October 2011, he was responsible for Global Sales & Marketing, Procurement, Licensing and CMO Business Development of Pharmaceuticals, Agrochemicals and Fine Chemicals at Mitsubishi Corporation and its affiliated companies for more than 25 years.